Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
| العنوان: | Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study |
|---|---|
| المؤلفون: | Anna-Karin Kroksmark, G. Campion, Judith C. van Deutekom, Marleen Van den Hauwe, R. Wilson, Mar Tulinius, Nathalie Goemans, Afrodite Lourbakos, Sjef J. de Kimpe, Gunnar Buyse |
| المصدر: | PLoS ONE, Vol 11, Iss 9, p e0161955 (2016) PLoS ONE |
| بيانات النشر: | Public Library of Science (PLoS), 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Heredity, Muscle Physiology, Muscle Functions, Physiology, Genetic Linkage, Epidemiology, Biopsy, Duchenne muscular dystrophy, Oligonucleotides, Walking, Duchenne Muscular Dystrophy, Biochemistry, Muscular Dystrophies, Dystrophin, 0302 clinical medicine, Medicine and Health Sciences, Biomechanics, Muscular dystrophy, Child, Routes of Administration, Multidisciplinary, Treatment Outcome, Neurology, X-Linked Traits, Sex Linkage, Child, Preschool, Anesthesia, Cohort, Medicine, Research Article, medicine.medical_specialty, Adolescent, Science, Surgical and Invasive Medical Procedures, 03 medical and health sciences, Pharmacokinetics, Genetics, medicine, Humans, Dosing, Muscle, Skeletal, Adverse effect, Drisapersen, Pharmacology, Clinical Genetics, Biological Locomotion, business.industry, Biology and Life Sciences, Proteins, medicine.disease, Surgery, Muscular Dystrophy, Duchenne, Clinical trial, Cytoskeletal Proteins, Natural History of Disease, 030104 developmental biology, Subcutaneous Injections, Exercise Test, business, 030217 neurology & neurosurgery |
| الوصف: | BackgroundDrisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.MethodsThis 188-week open-label extension of the dose-escalation study assessed the long-term efficacy, safety, and pharmacokinetics of drisapersen (PRO051/GSK2402968), 6 mg/kg subcutaneously, in 12 DMD subjects. Dosing was once weekly for 72 weeks. All subjects had a planned treatment interruption (weeks 73-80), followed by intermittent dosing (weeks 81-188).ResultsSubjects received a median (range) total dose of 5.93 (5.10 to 6.02) mg/kg drisapersen. After 177 weeks (last efficacy assessment), median (mean [SD]) six-minute walk distance (6MWD) improved by 8 (-24.5 [161]) meters for the 10 subjects able to complete the 6MWD at baseline (mean age [SD]: 9.5 [1.9] years). These statistics include 2 subjects unable to complete the test at later visits and who scored "zero". When only the 8 ambulant subjects at week 177 were taken into account, a median (mean [SD]) increase of 64 (33 [121]) meters in 6MWD was observed. Of 7 subjects walking ≥330 m at extension baseline, 5 walked farther at week 177. Of 3 subjects walking ConclusionDrisapersen was generally well tolerated over 188 weeks. Possible renal effects, thrombocytopenia and injection-site reactions warrant continued monitoring. Improvements in the 6MWD at 12 weeks were sustained after 3.4 years of dosing for most patients. For a small, uncontrolled study, the outcomes are encouraging, as natural history studies would anticipate a decline of over 100 meters over a 3-year period in a comparable cohort.Trial registrationClinicalTrials.gov NCT01910649. |
| تدمد: | 1932-6203 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a66d854fa2a6a9623e3f001f154722dTest https://doi.org/10.1371/journal.pone.0161955Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1a66d854fa2a6a9623e3f001f154722d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|